Abstract
G protein-coupled CB1 cannabinoid receptors are found in high density in the nervous system. CB1 cannabinoid receptors have the ability to change conformation between inactive and active receptor states in the absence of agonists. The ability to adopt an active conformation in the absence of agonists results in constitutive receptor signaling. Inverse agonists reverse the constitutive activity of the receptor in the absence of agonists also antagonize receptor activity due to the presence of agonists. This dual effect of the CB1 cannabinoid receptor inverse agonist SR141716A is a result of its ability to bind both inactive and active receptors, but with a relatively higher affinity for the inactive receptor. The higher affinity of SR141716A for the inactive receptor is due to its ability to hydrogen bond to lysine 3.28 in transmembrane helix 3, a residue available to SR141716A only in the inactive state.
Keywords: Protein-Coupling, transmembrane, SR141716A
Current Neuropharmacology
Title: Cannabinoid Receptor G Protein-Coupling and Inverse Agonism
Volume: 2 Issue: 1
Author(s): Deborah L. Lewis
Affiliation:
Keywords: Protein-Coupling, transmembrane, SR141716A
Abstract: G protein-coupled CB1 cannabinoid receptors are found in high density in the nervous system. CB1 cannabinoid receptors have the ability to change conformation between inactive and active receptor states in the absence of agonists. The ability to adopt an active conformation in the absence of agonists results in constitutive receptor signaling. Inverse agonists reverse the constitutive activity of the receptor in the absence of agonists also antagonize receptor activity due to the presence of agonists. This dual effect of the CB1 cannabinoid receptor inverse agonist SR141716A is a result of its ability to bind both inactive and active receptors, but with a relatively higher affinity for the inactive receptor. The higher affinity of SR141716A for the inactive receptor is due to its ability to hydrogen bond to lysine 3.28 in transmembrane helix 3, a residue available to SR141716A only in the inactive state.
Export Options
About this article
Cite this article as:
Lewis L. Deborah, Cannabinoid Receptor G Protein-Coupling and Inverse Agonism, Current Neuropharmacology 2004; 2 (1) . https://dx.doi.org/10.2174/1570159043476891
DOI https://dx.doi.org/10.2174/1570159043476891 |
Print ISSN 1570-159X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6190 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Neural Induction of Adult Bone Marrow and Umbilical Cord Stem Cells
Current Neurovascular Research Review on the Protective Effects of PACAP in Models of Neurodegenerative Diseases In Vitro and In Vivo
Current Pharmaceutical Design Conformational Changes Preceding Amyloid-Fibril Formation of Amyloid- Beta, Prion Protein and Stefin B; Parallels in pH Dependence
Medicinal Chemistry Reviews - Online (Discontinued) Effects of Maternal Choline Supplementation on the Septohippocampal Cholinergic System in the Ts65Dn Mouse Model of Down Syndrome
Current Alzheimer Research Clinical Significance of Cytokines and Chemokines in Neuropsychiatric Systemic Lupus Erythematosus
Current Rheumatology Reviews Exploiting the Diversity of the Heat-Shock Protein Family for Primary and Secondary Tauopathy Therapeutics
Current Neuropharmacology Inhibitory Effect of Ebselen on Cerebral Acetylcholinesterase Activity In Vitro: Kinetics and Reversibility of Inhibition
Current Pharmaceutical Design Humanin: A Possible Linkage Between Alzheimer’s Disease and Type 2 Diabetes
CNS & Neurological Disorders - Drug Targets A Review of Biomarkers in Mood and Psychotic Disorders: A Dissection of Clinical vs. Preclinical Correlates
Current Neuropharmacology New Challenges in CNS Repair: The Immune and Nervous Connection
Current Immunology Reviews (Discontinued) Regulation of Corticostriatal Synaptic Plasticity by G Protein-Coupled Receptors
CNS & Neurological Disorders - Drug Targets Role of Prolyl Endopeptidase in Intracellular Transport and Protein Secretion
CNS & Neurological Disorders - Drug Targets Polyamine Modulation of NMDARs as a Mechanism to Reduce Effects of Alcohol Dependence
Recent Patents on CNS Drug Discovery (Discontinued) Is Nitric Oxide Assuming a Janus-Face in The Central Nervous System?
Current Medicinal Chemistry Ion Channels and Epilepsy
Current Pharmaceutical Design Protein Kinase C Isozymes: Memory Therapeutic Potential
Current Drug Targets - CNS & Neurological Disorders A Closer Look at α-Secretase
Current Alzheimer Research Cell Culture Models of Oxidative Stress and Injury in the Central Nervous System
Current Neurovascular Research Preclinical Evaluation of Efficacy and Safety of an Improved Lentiviral Vector for the Treatment of β-Thalassemia and Sickle Cell Disease
Current Gene Therapy Overview of SLC22A and SLCO Families of Drug Uptake Transporters in the Context of Cancer Treatments
Current Drug Metabolism